Fig. 5

Canakinumab reduces MMP-2 expression and enzymatic activity induced by IL-1β in LX-2 cells. a Gene expression of Mmp-2 evaluated by Real-Time PCR in LX-2 cells treated with TGF-β (10 ng/ml), IL-1β (10 ng/ml) in presence and absence of Canakinumab. Expression levels were normalized to Gapdh. Mean ± SD of three different experiments performed in triplicate. b Gelatin zymography shows the activity of MMP-2 in the conditioned media of HK-2 cells treated for 24 h with TGF-β (10 ng/ml) or IL-1β (10 ng/ml) in the presence or absence of Canakinumab (5 μg/ml). c Histogram represents the densitometry analysis of the enzymatic activity as a mean ± SD of three experiments performed in triplicate. The p value was calculated with the t-test. *p < 0.05, **p < 0.01 versus untreated control cells (CTR); ^°°p < 0.01 vs TGF-β untreated; ^##p < 0.01 vs IL-1β untreated